GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 518
- Registration Number
- NCT02794571
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)
- Conditions
- Interventions
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT02749630
- Locations
- 🇬🇧
Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
🇩🇪Charité Research Organisation GmbH, Berlin, Germany
A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02748642
- Locations
- 🇺🇸
New Orleans Center for Clinical Research; Volunteer Research Group, Knoxville, Tennessee, United States
A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT02742779
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
Study to Investigate the Effect of Formulation and Food on the Pharmacokinetics of GDC-0810
- Conditions
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02722018
- Locations
- 🇬🇧
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02699710
- Locations
- 🇬🇧
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02698566
- Locations
- 🇺🇸
Southeastern Retina Associates, Chattanooga, Tennessee, United States
🇺🇸Char Eye Ear &Throat Assoc, Charlotte, North Carolina, United States
🇺🇸Paducah Retinal Center, Paducah, Kentucky, United States
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT02688985
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Massachusetts Medical School, Worcester, Massachusetts, United States
A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02655614
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
🇺🇸Forbes Norris Mda/als Ctr; Research Center, San Francisco, California, United States
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02640092
- Locations
- 🇺🇸
Molecular NeuroImaging, New Haven, Connecticut, United States
🇺🇸Bio Behavioral Health, Toms River, New Jersey, United States
🇺🇸NeuroCognitive Institute, Mount Arlington, New Jersey, United States